Pasithea Therapeutics (KTTA) EBIT (2021 - 2024)
Historic EBIT for Pasithea Therapeutics (KTTA) over the last 4 years, with Q4 2024 value amounting to -$3.3 million.
- Pasithea Therapeutics' EBIT rose 3669.28% to -$3.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$14.2 million, marking a year-over-year increase of 1082.27%. This contributed to the annual value of -$14.2 million for FY2024, which is 1082.27% up from last year.
- According to the latest figures from Q4 2024, Pasithea Therapeutics' EBIT is -$3.3 million, which was up 3669.28% from -$3.0 million recorded in Q3 2024.
- Pasithea Therapeutics' 5-year EBIT high stood at -$549609.0 for Q1 2021, and its period low was -$5.1 million during Q4 2023.
- For the 4-year period, Pasithea Therapeutics' EBIT averaged around -$3.0 million, with its median value being -$3.2 million (2023).
- Per our database at Business Quant, Pasithea Therapeutics' EBIT tumbled by 33749.96% in 2022 and then skyrocketed by 3669.28% in 2024.
- Quarter analysis of 4 years shows Pasithea Therapeutics' EBIT stood at -$2.0 million in 2021, then tumbled by 106.66% to -$4.0 million in 2022, then dropped by 27.36% to -$5.1 million in 2023, then surged by 36.69% to -$3.3 million in 2024.
- Its last three reported values are -$3.3 million in Q4 2024, -$3.0 million for Q3 2024, and -$3.9 million during Q2 2024.